BR112022011280A2 - Anticorpo anti-cd5 para o tratamento da disfunção do espectro da neuromielite óptica - Google Patents
Anticorpo anti-cd5 para o tratamento da disfunção do espectro da neuromielite ópticaInfo
- Publication number
- BR112022011280A2 BR112022011280A2 BR112022011280A BR112022011280A BR112022011280A2 BR 112022011280 A2 BR112022011280 A2 BR 112022011280A2 BR 112022011280 A BR112022011280 A BR 112022011280A BR 112022011280 A BR112022011280 A BR 112022011280A BR 112022011280 A2 BR112022011280 A2 BR 112022011280A2
- Authority
- BR
- Brazil
- Prior art keywords
- dysfunction
- antibody
- treatment
- neuromyelitis
- optic spectrum
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962945644P | 2019-12-09 | 2019-12-09 | |
| PCT/US2020/063781 WO2021118999A1 (en) | 2019-12-09 | 2020-12-08 | Anti-c5 antibody for the treatment of neuromyelitis optica spectrum disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022011280A2 true BR112022011280A2 (pt) | 2022-09-06 |
Family
ID=74046204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022011280A BR112022011280A2 (pt) | 2019-12-09 | 2020-12-08 | Anticorpo anti-cd5 para o tratamento da disfunção do espectro da neuromielite óptica |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12612451B2 (https=) |
| EP (1) | EP4073110A1 (https=) |
| JP (2) | JP7789672B2 (https=) |
| KR (1) | KR20220110827A (https=) |
| CN (2) | CN119548622A (https=) |
| AU (1) | AU2020401102A1 (https=) |
| BR (1) | BR112022011280A2 (https=) |
| CA (1) | CA3161271A1 (https=) |
| CO (1) | CO2022009246A2 (https=) |
| MX (1) | MX2022007116A (https=) |
| WO (1) | WO2021118999A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3251727A1 (en) * | 2022-05-04 | 2023-11-09 | Alexion Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF A DISORDER ON THE SPECTRUM OF OPTICAL NEUROMYELITIS |
| WO2025221479A1 (en) * | 2024-04-16 | 2025-10-23 | Alexion Pharmaceuticals, Inc. | Biomarkers for monitoring effective treatment of neuromyelitis optica spectrum disorder (nmosd) with complement component c5 inhibitors |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5135916A (en) | 1989-06-12 | 1992-08-04 | Oklahoma Medical Research Foundation | Inhibition of complement mediated inflammatory response |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US20090220508A1 (en) | 2006-03-15 | 2009-09-03 | Alexion Pharmaceuticals, Inc. | Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| CA2742802C (en) | 2008-11-10 | 2019-11-26 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
| JO3437B1 (ar) * | 2009-10-30 | 2019-10-20 | Esai R & D Man Co Ltd | أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها |
| BR112012027917A2 (pt) | 2010-04-30 | 2017-11-28 | Alexion Pharma Inc | anticorpos que apresentam reduzida imunogenicidade em um indivíduo humano |
| MX340696B (es) * | 2010-04-30 | 2016-07-21 | Alexion Pharma Inc | Anticuerpos anti-c5a y metodos para usar los anticuerpos. |
| TW201241008A (en) * | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
| IL288931B2 (en) | 2013-03-14 | 2025-05-01 | Alnylam Pharmaceuticals Inc | Compositions comprising a complementary portion of C5 IRNA and methods of using them |
| SI3011345T1 (sl) | 2013-08-07 | 2017-12-29 | Alexion Pharmaceuticals, Inc. | Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus) |
| NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| BR112017011235A2 (pt) | 2014-12-19 | 2018-02-06 | Chugai Pharmaceutical Co Ltd | anticorpos anti-c5 e métodos de uso |
| EP3313437A1 (en) * | 2015-06-26 | 2018-05-02 | Alexion Pharmaceuticals, Inc. | A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant |
| EP3402816A1 (en) * | 2016-01-11 | 2018-11-21 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment |
| CN116769024A (zh) | 2016-06-14 | 2023-09-19 | 瑞泽恩制药公司 | 抗c5抗体及其用途 |
| ES2999550T3 (en) * | 2017-03-31 | 2025-02-26 | Alexion Pharma Inc | Method for simultaneous quantification of alxn1210 and eculizumab in human serum or urine |
| US20200095307A1 (en) | 2018-09-21 | 2020-03-26 | Alexion Pharmaceuticals, Inc. | Compositions and methods for the treatment of neuromyelitis optica |
| EP4135837A1 (en) | 2020-04-16 | 2023-02-22 | Assistance Publique, Hopitaux De Paris | Methods for treating a complement mediated disorder caused by viruses |
| CN116437913A (zh) | 2020-09-23 | 2023-07-14 | 艾其林医药公司 | 用于治疗补体介导的病症的药物化合物 |
| CA3251727A1 (en) | 2022-05-04 | 2023-11-09 | Alexion Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF A DISORDER ON THE SPECTRUM OF OPTICAL NEUROMYELITIS |
| WO2025221479A1 (en) | 2024-04-16 | 2025-10-23 | Alexion Pharmaceuticals, Inc. | Biomarkers for monitoring effective treatment of neuromyelitis optica spectrum disorder (nmosd) with complement component c5 inhibitors |
-
2020
- 2020-12-08 KR KR1020227023328A patent/KR20220110827A/ko active Pending
- 2020-12-08 AU AU2020401102A patent/AU2020401102A1/en active Pending
- 2020-12-08 CN CN202411616594.9A patent/CN119548622A/zh active Pending
- 2020-12-08 JP JP2022534708A patent/JP7789672B2/ja active Active
- 2020-12-08 MX MX2022007116A patent/MX2022007116A/es unknown
- 2020-12-08 EP EP20829482.7A patent/EP4073110A1/en active Pending
- 2020-12-08 BR BR112022011280A patent/BR112022011280A2/pt unknown
- 2020-12-08 WO PCT/US2020/063781 patent/WO2021118999A1/en not_active Ceased
- 2020-12-08 US US17/783,106 patent/US12612451B2/en active Active
- 2020-12-08 CA CA3161271A patent/CA3161271A1/en active Pending
- 2020-12-08 CN CN202080085425.0A patent/CN114867747A/zh active Pending
-
2022
- 2022-07-01 CO CONC2022/0009246A patent/CO2022009246A2/es unknown
-
2025
- 2025-03-03 JP JP2025032847A patent/JP2025084932A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3161271A1 (en) | 2021-06-17 |
| JP2023504209A (ja) | 2023-02-01 |
| CN119548622A (zh) | 2025-03-04 |
| CO2022009246A2 (es) | 2022-07-29 |
| KR20220110827A (ko) | 2022-08-09 |
| US20230043034A1 (en) | 2023-02-09 |
| MX2022007116A (es) | 2022-07-11 |
| AU2020401102A1 (en) | 2022-07-21 |
| WO2021118999A1 (en) | 2021-06-17 |
| JP7789672B2 (ja) | 2025-12-22 |
| JP2025084932A (ja) | 2025-06-03 |
| CN114867747A (zh) | 2022-08-05 |
| US12612451B2 (en) | 2026-04-28 |
| EP4073110A1 (en) | 2022-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2020000245A (es) | Anticuerpos il-11 | |
| CL2020003071A1 (es) | Proteínas de unión multiespecíficas y mejoras con estas | |
| CL2020003096A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| UY39798A (es) | Anticuerpos anti-ccr8 y usos de los mismos | |
| CO2020004831A2 (es) | Dosis y administración de anticuerpos antic-c5 para el tratamiento de pacientes con glomerulonefritis membranoproliferativa | |
| ECSP17005649A (es) | Anticuerpos anti-tau humanizados | |
| CL2020003218A1 (es) | Anticuerpos dirigidos contra il-11ra | |
| BR112021008060A2 (pt) | Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento | |
| EA201990296A1 (ru) | Антитела против siglec-7 для лечения рака | |
| EA201790339A1 (ru) | Комбинированные препараты с антителами к cd40 | |
| MX2022001841A (es) | Anticuerpos contra ilt2 y uso de los mismos. | |
| MX2021008919A (es) | Dosis y administracion de anticuerpos anti-c5 para el tratamiento del sindrome uremico hemolitico atipico (shua). | |
| BR112020015498A8 (pt) | Anticorpos anti-pd-1 | |
| CL2023003694A1 (es) | Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, métodos de uso | |
| MX2022002672A (es) | Anticuerpo anti-vsig4 o fragmento de union a antigeno y usos del mismo. | |
| BR112021013397A2 (pt) | Anticorpos anti-tigit | |
| BR112022011280A2 (pt) | Anticorpo anti-cd5 para o tratamento da disfunção do espectro da neuromielite óptica | |
| CL2019003485A1 (es) | Métodos para redicur la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a. (divisional solicitud 201900909) | |
| EA202190647A1 (ru) | Антитела к klrg1 | |
| MX2021009789A (es) | Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de miastenia gravis generalizada. | |
| BR112022021641A2 (pt) | Tratamento de combinação de anticorpos anti-cd40 para câncer | |
| CL2022002727A1 (es) | Anticuerpo anti-cd47 y usos del mismo | |
| HK40078839A (en) | Anti-c5 antibody for the treatment of neuromyelitis optica spectrum disorder | |
| EA202090309A1 (ru) | Анти-tigit антитела | |
| EA202192249A1 (ru) | Доза и введение антител к c5 для лечения генерализованной миастении гравис |